Lv1
30 积分 2025-04-01 加入
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
15天前
已完结
Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead
1个月前
已完结
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
1个月前
已完结
Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target
1个月前
已完结
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
2个月前
已完结
TYK2: an emerging therapeutic target in rheumatic disease
2个月前
已完结
JAK inhibitor selectivity: new opportunities, better drugs?
2个月前
已完结
iAutoEvoLab as an all-in-one laboratory for programmable protein evolution
3个月前
已完结
Prevalence of Elevated Lipoprotein(a) and its Association With Subclinical Atherosclerosis in 2.9 Million Chinese Adults
3个月前
已完结
Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma
4个月前
已完结
皖公网安备34019202002308
